Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Philip N Sambrook, Christian Roux, Jean-Pierre Devogelaer, Kenneth Saag, Chak-Sing Lau, Jean-Yves Reginster, Christina Bucci-Rechtweg, Guoqin Su, David M Reid

Research output: Contribution to journalArticle

35 Citations (Scopus)


We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).
Original languageEnglish
Pages (from-to)289-295
Number of pages7
Issue number1
Publication statusPublished - Jan 2012


Cite this